Prolonged IgM Antibody Response in People Infected with Zika Virus: Implications for Interpreting Serologic Testing Results for Pregnant Women

Summary

In July 2016, CDC issued Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure – United States, July 2016 (https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm) that includes Zika virus immunoglobulin M (IgM) testing of pregnant women. However, some flavivirus infections can result in prolonged IgM responses (>12 weeks) that make it difficult to determine the timing of infection, especially in testing of asymptomatic people. Emerging epidemiologic and laboratory data indicate that Zika virus IgM can persist beyond 12 weeks in a subset of infected people. Therefore, detection of IgM may not always indicate a recent infection. Although IgM persistence could affect IgM test interpretation for all infected people, it would have the greatest effect on clinical management of pregnant women with a history of living in or traveling to areas with Zika virus transmission. Pregnant women who test positive for IgM antibody may have been infected with Zika virus and developed an IgM response before conception.

For asymptomatic pregnant women with a history of living in or traveling to areas with Zika virus transmission, Zika virus nucleic acid test (NAT) testing at least once per trimester is recommended, in addition to IgM testing as previously recommended. If positive, this may provide a more definitive diagnosis of recent Zika infection. However, a negative NAT does not rule out recent infection because viral ribonucleic acid (RNA) declines over time. Other diagnostic methods, such as NAT testing of amniocentesis specimens or serial ultrasounds, may provide additional information to help determine whether the IgM test results suggest a recent infection. Providers should counsel women on the limitations of all tests. In addition, providers may wish to consider IgM testing as part of pre-conception counseling to establish baseline IgM results before pregnancy; however, preconception negative IgM results might have limited value for...
women at ongoing risk of Zika infection. NAT testing should be performed for any pregnant woman who becomes symptomatic or who has a sexual partner who tests positive for Zika virus infection.

**Recommendations**

For asymptomatic pregnant women with possible Zika virus exposure before conception, (particularly women who lived in or traveled to areas with posted CDC Zika Travel Notices [https://wwwnc.cdc.gov/travel/page/zika-information](https://wwwnc.cdc.gov/travel/page/zika-information)), CDC recommends that healthcare providers take these steps:

1) Screen pregnant women for risk of Zika exposure and symptoms of Zika. Promptly test pregnant women with NAT if they become symptomatic during their pregnancy or if a sexual partner tests positive for Zika virus infection.

2) Conduct NAT testing at least once per trimester, unless a previous test has been positive.*

3) Consider NAT testing of amniocentesis specimens if amniocentesis is performed for other reasons.†


5) Consider IgM testing to determine baseline Zika virus IgM levels as part of preconception counseling.§ For more information about preconception counseling, see: [https://www.cdc.gov/zika/pdfs/preconception-counseling.pdf](https://www.cdc.gov/zika/pdfs/preconception-counseling.pdf)

Recommendations for testing symptomatic pregnant women, remain unchanged ([https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm](https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm)). However, if a symptomatic pregnant woman is IgM positive and NAT negative, and lived in or traveled to an area with a posted CDC Zika Travel Notice ([https://wwwnc.cdc.gov/travel/page/zika-information](https://wwwnc.cdc.gov/travel/page/zika-information)), healthcare providers should recognize that the positive IgM result does not necessarily indicate recent infection.

Background

Some flavivirus infections have been reported to result in prolonged IgM responses that make it difficult to differentiate recent from prior infections in areas with ongoing transmission. For dengue virus, IgM was determined to persist for 6 months (179 days [95% confidence interval, 155 to 215 days]) for primary infections and 4.6 months (139 days [95% confidence interval, 119 to 167 days]) after infection with another flavivirus. IgM antibodies against West Nile virus, another flavivirus related to Zika virus, have been detected in asymptomatic, infected blood donors for at least three months after they donated blood, and almost half of tested patients with West Nile virus infection had serum IgM antibodies >1 year after infection.

Recent findings suggest that Zika virus infection may also result in IgM persistence that may make it difficult to differentiate prior from recent infections. A recent study in Puerto Rico of symptomatic patients with NAT-confirmed Zika virus infection detected Zika virus IgM in 100% (28/28) of participants at 8 to 15 days after symptom onset, and 87% (52/60) at greater than 60 days after symptom onset. Unpublished data on the symptomatic patients from this ongoing study show a median time to first negative Zika virus IgM as 4 months (122 days [range 8-210 days]). More data are needed to accurately estimate the proportion of persons who are likely to have Zika IgM persist beyond 12 weeks after infection.

IgM test results can also be difficult to interpret because of cross-reactivity with other flaviviruses, particularly dengue virus, when a person has been previously infected or vaccinated with a related flavivirus. During 2016, Puerto Rico had limited dengue virus transmission and, therefore, people who tested positive for Zika IgM antibody could be assumed to have had recent Zika virus infection. However, if dengue virus transmission were to increase, guidance for interpretation of Zika virus IgM testing results may need to be reconsidered.

NAT testing may be useful in testing pregnant women as an indicator of current infection and increased risk to the fetus. In the same study from Puerto Rico discussed above, viral RNA was detected in 36% (10/28) of participants at 8–15 days after symptom onset, 21% (27/129) at 16–30 days after symptom onset, and 4% (3/79) more than 60 days after symptom onset. A limited number of studies have demonstrated detection of viral nucleic acid in some pregnant women for even longer periods after symptom onset. For example, three of the five pregnant women included in the study from Puerto Rico had detectable RNA at 46 days and one still had detectable RNA at 80 days after symptom onset. In another case series, some pregnant women had Zika virus RNA detectable up to 107 days after symptom onset.
For More Information


References


Footnotes

* Birth defects have been reported in a higher proportion of fetuses or infants whose mothers were infected during the first trimester of pregnancy than in later trimesters. In pregnancies with symptom onset or exposure during the first trimester that were
limited to those with laboratory-confirmed Zika virus infection, 15% of completed pregnancies had reported birth defects of the type seen with congenital Zika infection.† Consideration of amniocentesis should be individualized, because data about its usefulness in diagnosing congenital Zika virus infection are limited. The presence of Zika virus RNA in the amniotic fluid might indicate fetal infection; however, a negative result does not exclude congenital Zika virus infection.
§ Preconceptional IgM testing is recommended to establish a baseline IgM level before pregnancy. However, given the limitations of interpreting IgM testing, the results of these tests should not be used to guide decisions about pregnancy timing for women living in areas with ongoing risk of transmission.
DHEC contact information for reportable diseases and reporting requirements

Reporting of Zika is consistent with South Carolina Law requiring the reporting of diseases and conditions to your state or local public health department. (State Law # 44-29-10 and Regulation # 61-20) as per the DHEC 2017 List of Reportable Conditions available at: http://www.scdhec.gov/Library/CR-009025.pdf

Federal HIPAA legislation allows disclosure of protected health information, without consent of the individual, to public health authorities to collect and receive such information for the purpose of preventing or controlling disease. (HIPAA 45 CFR §164.512).

<table>
<thead>
<tr>
<th>Regional Public Health Offices – 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mail or call reports to the Epidemiology Office in each Public Health Region</td>
</tr>
</tbody>
</table>

**MAIL TO:**

<table>
<thead>
<tr>
<th>Lowcountry</th>
<th>Midlands</th>
<th>Pee Dee</th>
<th>Upstate</th>
</tr>
</thead>
<tbody>
<tr>
<td>4050 Bridge View Drive, Suite 600</td>
<td>2000 Hampton Street</td>
<td>145 E. Cheves Street</td>
<td>200 University Ridge</td>
</tr>
<tr>
<td>N. Charleston, SC 29405</td>
<td>Columbia, SC 29204</td>
<td>Florence, SC 29506</td>
<td>Greenville, SC 29602</td>
</tr>
<tr>
<td>Fax: (843) 953-0051</td>
<td>Fax: (803) 576-2993</td>
<td>Fax: (843) 661-4859</td>
<td>Fax: (864) 282-4373</td>
</tr>
</tbody>
</table>

**CALL TO:**

<table>
<thead>
<tr>
<th>Lowcountry</th>
<th>Midlands</th>
<th>Pee Dee</th>
<th>Upstate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berkeley, Charleston, Dorchester</td>
<td>Kershaw, Lexington, Newberry, Richland</td>
<td>Chesterfield, Darlington, Dillon, Florence, Marlboro, Marion</td>
<td>Anderson, Oconee</td>
</tr>
<tr>
<td>Phone: (843) 953-0043</td>
<td>Phone: (803) 576-2749</td>
<td>Phone: (843) 861-4830</td>
<td>Phone: (864) 260-5581</td>
</tr>
<tr>
<td>Nights/Weekends: (843) 441-1091</td>
<td>Nights/Weekends: (888) 801-1046</td>
<td>Nights/Weekends: (843) 915-8845</td>
<td>Nights/Weekends: (886) 298-4442</td>
</tr>
<tr>
<td>Beaufort, Colleton, Hampton, Jasper</td>
<td>Chester, Fairfield, Lancaster, York</td>
<td>Clarendon, Lee, Sumter</td>
<td>Abbeville, Greenwood, McCormick</td>
</tr>
<tr>
<td>Phone: (843) 322-2453</td>
<td>Phone: (803) 286-9948</td>
<td>Phone: (803) 773-5511</td>
<td>Phone: (864) 260-5581</td>
</tr>
<tr>
<td>Nights/Weekends: (843) 441-1091</td>
<td>Nights/Weekends: (888) 801-1046</td>
<td>Nights/Weekends: (843) 915-8845</td>
<td>Nights/Weekends: (886) 298-4442</td>
</tr>
<tr>
<td>Allendale, Bamberg, Calhoun, Orangeburg</td>
<td>Aiken, Barnwell, Edgefield, Saluda</td>
<td>Georgetown, Horry, Williamsburg</td>
<td>Cherokee, Greenville, Laurens</td>
</tr>
<tr>
<td>Phone: (803) 268-5833</td>
<td>Phone: (803) 642-1618</td>
<td>Phone: (843) 915-8804</td>
<td>Phone: (864) 372-3133</td>
</tr>
<tr>
<td>Nights/Weekends: (843) 441-1091</td>
<td>Nights/Weekends: (888) 801-1046</td>
<td>Nights/Weekends: (843) 915-8845</td>
<td>Nights/Weekends: (866) 298-4442</td>
</tr>
</tbody>
</table>

For information on reportable conditions, see http://www.scdhec.gov/Health/FHPF/ReportDiseasesAdverseEvents/ReportableConditionsInSC/

### Categories of Health Alert messages:

- **Health Alert** Conveys the highest level of importance; warrants immediate action or attention.
- **Health Advisory** Provides important information for a specific incident or situation; may not require immediate action.
- **Health Update** Provides updated information regarding an incident or situation; unlikely to require immediate action.
- **Info Service** Provides general information that is not necessarily considered to be of an emergent nature.

DHEC Bureau of Disease Control
Division of Acute Disease Epidemiology
2100 Bull St ∙ Columbia, SC 29201
Phone: (803) 898-0861 ∙ Fax: (803) 898-0897
Nights / Weekends: 1-888-847-0902